Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
Edgar Carnero ContenttiJorge CorrealePublished in: Drug design, development and therapy (2022)
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration. Basic and translational studies have shown that B cells and myeloid cells are critical players for the development and course of the disease. Bruton's tyrosine kinase (BTK) is essential for B cell receptor-mediated B cell activation and for normal B cell development and maturation. In addition to its role in B cells, BTK is also involved in several functions of myeloid cells. Although significant number of disease-modifying treatments (DMTs) have been approved for clinical use in MS patients, novel targeted therapies should be studied in refractory patients and patients with progressive forms of the disease. On the basis of its role in B cells and myeloid cells, BTK inhibitors can provide attractive therapeutic benefits for MS. In this article, we review the main effects of BTK inhibitors on different cell types involved in the pathogenesis of MS and summarise recent advances in the development of BTK inhibitors as novel therapeutic approaches in different MS clinical trials. Available data regarding the efficacy and safety of these drugs are described.
Keyphrases
- tyrosine kinase
- multiple sclerosis
- epidermal growth factor receptor
- mass spectrometry
- induced apoptosis
- end stage renal disease
- ms ms
- clinical trial
- ejection fraction
- cell cycle arrest
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- white matter
- peritoneal dialysis
- dendritic cells
- oxidative stress
- signaling pathway
- cell death
- immune response
- mesenchymal stem cells
- cell therapy
- cell proliferation
- patient reported outcomes
- deep learning
- pi k akt